Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Glycine-zipper-derived synthetic amino acid-containing peptides as amyloid-β aggregation inhibitors: structural and mechanistic investigations.

Bioorganic chemistry·2026

Same author

Synthesis of Carbamoylated Phenylalanine Derivatives and Peptide Modification via Palladium-Catalyzed Ex Situ CO Insertion.

The Journal of organic chemistry·2026

Same author

HFIP-Promoted Strain-Release-Driven Functionalization of Azabicyclo[1.1.0]butanes with Heterocyclobutane Trichloroacetimidates.

Organic letters·2026

Same author

Advances in Five-Membered Heterocyclic Scaffolds as Anti-Tuberculosis Agents: A Decade of Discovery.

Archiv der Pharmazie·2026

Same author

Straightforward Synthesis of Quinoline Sulfonamides via Aminosulfonylation Using a Bench-Stable SO<sub>2</sub> Surrogate.

The Journal of organic chemistry·2025

Same author

Microwave-Assisted Precise Synthesis of Alkyl/Aryl-Modified Triazolyl-Phenylalanine Hybrids and Peptide Modifications through Multicomponent Reaction.

Organic letters·2025

Same journal

Design, synthesis, and <i>in silico</i> and <i>in vitro</i> evaluation of novel complex naphthalimide-ciprofloxacin hybrids as next-generation antimicrobial agents.

RSC medicinal chemistry·2026

Same journal

3-Hydroxypyrimidine-2,4-dione derivatives as monkeypox virus resolvase (Mpr) inhibitors.

RSC medicinal chemistry·2026

Same journal

Design and synthesis of <i>N</i>-3-substituted quinazolinone derivatives as anticancer agents targeting EGFR.

RSC medicinal chemistry·2026

Same journal

Structure-activity relationship for calanthoside, a potential hair-growth stimulant with an indole 2-<i>S</i>-,3-<i>O</i>-bis-glucoside structure. Part 1: role of two glucoside moieties in promoting HFDPC proliferation.

RSC medicinal chemistry·2026

Same journal

Rational design of an environment-sensitive fluorescent probe for monitoring butyrylcholinesterase activity and its application in Alzheimer's disease.

RSC medicinal chemistry·2026

Same journal

Polypharmacology in multi-drug-resistant tuberculosis: current scenario and future promise.

RSC medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 30, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Peptide-based amyloid-beta aggregation inhibitors.

Naina Sehra¹, Rajesh Parmar¹, Rahul Jain¹

¹Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Sector 67, S. A. S. Nagar Punjab 160062 India rahuljain@niper.ac.in.

RSC Medicinal Chemistry

|January 30, 2025

Summary

This summary is machine-generated.

Aberrant protein misfolding, a hallmark of neurodegenerative diseases like Alzheimer's, can be targeted by novel peptide-based inhibitors designed to prevent amyloid-beta aggregation and its associated cognitive decline.

More Related Videos

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

Related Experiment Videos

Last Updated: May 30, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain

Published on: October 25, 2017

Area of Science:

Neuroscience
Biochemistry
Drug Discovery

Background:

Aberrant protein misfolding and aggregation are central to neurodegenerative disorders such as Alzheimer's disease (AD).
Amyloid-beta (Aβ) peptide aggregation forms toxic fibrils, leading to cognitive dysfunction and memory loss in AD.
Targeting Aβ aggregation is a key strategy in AD drug development.

Purpose of the Study:

To review rationally designed peptide and mimetic molecules as inhibitors of amyloid-beta aggregation.
To highlight various peptide-based therapeutic strategies for Alzheimer's disease.

Main Methods:

Review of structure-based peptides, metal-peptide chelators, stapled peptides, and peptide-based nanomaterials.
Analysis of therapeutic approaches targeting amyloid-beta aggregation pathways.

Main Results:

Peptide-based approaches show promise in inhibiting Aβ aggregation.
Diverse molecular designs, including nanomaterials, offer potential for Aβ inhibition.

Conclusions:

Rationally designed peptides and mimetics represent a promising avenue for developing novel Alzheimer's disease therapeutics.
Further research into these peptide-based inhibitors could lead to effective treatments for cognitive decline associated with AD.